Whether you are a new T1D Family, a TrialNet participant, a healthcare provider, or a researcher — you'll find resources here.
We’re here to help you after a new T1D diagnosis. Get answers to frequently asked questions and learn about clinical studies testing ways to maintain insulin production.
While you wait for screening results, get answers to your questions, find out about next steps, and learn more about TrialNet’s Pathway to Prevention.
Your T1D families are important to you. Learn how easy it is to connect your patients with world-class T1D research.
Vanderbilt University Medical Center is one of twenty-five type 1 diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Bill Russell, MD, the TrialNet team at Vanderbilt is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.
Atlanta Diabetes Association
1800 Howell Mill Rd, # 450, Atlanta, GA 30318
AM Diabetes & Endocrinology Center
3025 Kate Bond Rd, Bartlett, TN 38133
University Diabetes & Endocrine Consultants
5616 Brainerd Road, Suite 208, Chattanooga, TN 37411
Midwest Endocrinology, LLC
380 N. Terra Cotta Rd. Ste A, Crystal Lake, IL 60012
Physicians East PA
1006 W.H. Smith Blvd, Greenville, NC 27834
University of Mississippi Medical Center
2500 N State ST, Jackson, MS 39209
Holston Medical Group Clinical Research
105 West Stone Drive, Suite 3B, Kingsport, TN 37660
Kentucky Diabetes Endocrinology Center
1760 Nicholasville Road Suite 502, Lexington, KY 40503
University of Louisville Pediatric Endocrinology
601 S. Floyd St, Louisville, KY 40202
University of Tennessee/ Methodist Le Bonheur Healthcare
50 N Dunlop St, 7th Floor PCRU, Memphis, TN 38103
Baptist Memorial Medical Group, Inc.
5659 South Rex Rd, Memphis, TN 38119
If you have a relative with T1D, you’re in a unique position to help us learn more about the disease and how to stop it. The first step is to sign up for Pathway to Prevention screening to determine your risk of developing T1D.
TrialNet is testing the drug abatacept to see if it can delay or prevent progression of early stage T1D (stage 1 to stage 2) and ultimately prevent clinical diagnosis (stage 3). In earlier studies for people newly diagnosed (stage 3), abatacept helped slow down disease progression.
We tested the drug teplizumab to see if it could delay or prevent progression of early stage T1D (stage 2) and prevent clinical diagnosis (stage 3). In earlier studies in people newly diagnosed (stage 3), teplizumab helped to prolong insulin production.
We are testing the drug hydroxychloroquine (HCQ) to see if it can delay or prevent early stage T1D (stage 1) from progressing to abnormal glucose tolerance (stage 2) and ultimately prevent clinical diagnosis (stage 3). HCQ is already used to reduce symptoms and progression of other autoimmune diseases, such as rheumatoid arthritis and lupus. This is the first study to see if it can prevent or delay T1D.
Once your study ends, we're still here for you. Participant monitoring and continued involvement helps us learn more about T1D.